Trelagliptin: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
== Trelagliptin == | |||
'''Trelagliptin''' is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as [[Dipeptidyl peptidase-4 inhibitors|DPP-4 inhibitors]], which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood sugar levels. | |||
== | === Mechanism of Action === | ||
Trelagliptin | Trelagliptin functions by inhibiting the enzyme [[Dipeptidyl peptidase-4|DPP-4]], which is responsible for the degradation of incretin hormones such as [[glucagon-like peptide-1|GLP-1]] and [[glucose-dependent insulinotropic polypeptide|GIP]]. By preventing the breakdown of these hormones, trelagliptin increases their concentration in the bloodstream, leading to improved insulin secretion and decreased glucagon release, ultimately resulting in better glycemic control. | ||
==Clinical Use== | === Clinical Use === | ||
Trelagliptin is | Trelagliptin is prescribed for the treatment of type 2 diabetes in adults. It is typically used in conjunction with diet and exercise to improve blood sugar control. Unlike some other DPP-4 inhibitors, trelagliptin is administered once weekly, which may improve patient adherence to the treatment regimen. | ||
==Side Effects== | === Side Effects === | ||
Common side effects of trelagliptin include headache, upper respiratory tract | Common side effects of trelagliptin include nasopharyngitis, headache, and upper respiratory tract infections. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis, and patients should be monitored for symptoms of this condition. | ||
==Related | === History === | ||
* [[Dipeptidyl peptidase-4 | Trelagliptin was developed by [[Takeda Pharmaceutical Company|Takeda Pharmaceutical Company]] and was first approved for use in Japan in 2015. It is marketed under the brand name Zafatek. | ||
=== Research and Development === | |||
Ongoing research is focused on evaluating the long-term efficacy and safety of trelagliptin, as well as its potential benefits in combination with other antidiabetic agents. Studies are also exploring its impact on cardiovascular outcomes in patients with type 2 diabetes. | |||
== Related Pages == | |||
* [[Type 2 diabetes mellitus]] | |||
* [[Dipeptidyl peptidase-4 inhibitors]] | |||
* [[Incretin]] | * [[Incretin]] | ||
== References == | |||
[[Category: | {{Reflist}} | ||
[[Category: | |||
[[Category:Antidiabetic drugs]] | |||
[[Category:Dipeptidyl peptidase-4 inhibitors]] | |||
[[File:Trelagliptin.svg|thumb|Chemical structure of Trelagliptin]] | |||
[[File:Trelagliptin.jpg|thumb|Trelagliptin tablets]] | |||
<gallery> | |||
File:Trelagliptin.svg | |||
File:Trelagliptin.jpg | |||
</gallery> | |||
Latest revision as of 01:59, 17 February 2025
Trelagliptin[edit]
Trelagliptin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood sugar levels.
Mechanism of Action[edit]
Trelagliptin functions by inhibiting the enzyme DPP-4, which is responsible for the degradation of incretin hormones such as GLP-1 and GIP. By preventing the breakdown of these hormones, trelagliptin increases their concentration in the bloodstream, leading to improved insulin secretion and decreased glucagon release, ultimately resulting in better glycemic control.
Clinical Use[edit]
Trelagliptin is prescribed for the treatment of type 2 diabetes in adults. It is typically used in conjunction with diet and exercise to improve blood sugar control. Unlike some other DPP-4 inhibitors, trelagliptin is administered once weekly, which may improve patient adherence to the treatment regimen.
Side Effects[edit]
Common side effects of trelagliptin include nasopharyngitis, headache, and upper respiratory tract infections. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis, and patients should be monitored for symptoms of this condition.
History[edit]
Trelagliptin was developed by Takeda Pharmaceutical Company and was first approved for use in Japan in 2015. It is marketed under the brand name Zafatek.
Research and Development[edit]
Ongoing research is focused on evaluating the long-term efficacy and safety of trelagliptin, as well as its potential benefits in combination with other antidiabetic agents. Studies are also exploring its impact on cardiovascular outcomes in patients with type 2 diabetes.
Related Pages[edit]
References[edit]
<references group="" responsive="1"></references>
